VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LLY
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LLYEli Lilly and Company
$1415.55$1.33T
Overview & Tools
OverviewChart Terminal ↗AnalysisVisualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksLLYFinancials

Eli Lilly and Company (LLY) Income Statement

30Y historyFree accessUpdated daily

Revenue scaled more than twofold over the ten-quarter window while gross margin held near 84% (83.9% in 2026Q3), yet operating margin fell from 47.6% in 2025Q3 to 35.3% in 2026Q3, indicating operating income is growing more slowly than revenue.

Income StatementBalance SheetCash FlowRatios

LLY Income Statement

Annual statement

LLY Income Statement

Eli Lilly and Company (LLY) annual income statement — 30-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue86.46B65.18B45.04B34.12B28.54B28.32B24.54B22.32B21.49B19.97B21.22B19.96B19.62B23.11B22.6B24.29B23.08B21.84B20.37B18.63B15.69B14.65B13.86B12.58B11.08B11.54B10.86B10B9.24B7.99B7B
Revenue Growth %45.51%44.7%32%19.56%0.79%15.4%9.95%3.84%7.61%-5.88%6.33%1.75%-15.13%2.25%-6.93%5.25%5.68%7.19%9.33%18.75%7.14%5.68%10.14%13.59%-4.03%6.26%8.59%8.29%15.64%14.14%3.47%
Cost of Goods Sold14.15B11.05B8.42B7.08B6.63B7.31B5.48B4.72B4.68B4.45B5.71B5.04B4.93B4.91B4.8B5.07B4.37B4.25B4.38B4.25B3.55B3.47B3.22B2.68B2.18B2.16B1.62B1.66B1.52B1.44B1.33B
COGS % of Revenue-16.96%18.69%20.75%23.23%25.82%22.34%21.15%21.78%22.27%26.91%25.24%25.15%21.24%21.22%20.87%18.92%19.45%21.48%22.8%22.6%23.72%23.26%21.26%19.65%18.72%14.91%16.58%16.51%17.98%18.98%
Gross Profit72.31B54.13B36.63B27.04B21.91B21.01B19.06B17.6B16.81B15.53B15.51B14.92B14.68B18.2B17.81B19.22B18.71B17.59B16B14.38B12.14B11.17B10.63B9.91B8.9B9.38B9.24B8.34B7.71B6.55B5.67B
Gross Margin %83.63%83.04%81.31%79.25%76.77%74.18%77.66%78.85%78.22%77.73%73.09%74.76%74.85%78.76%78.78%79.13%81.08%80.55%78.52%77.2%77.4%76.28%76.74%78.74%80.35%81.28%85.09%83.42%83.49%82.02%81.02%
Gross Profit Growth %-47.79%35.44%23.41%4.31%10.23%8.29%4.68%8.28%0.09%3.96%1.62%-19.35%2.24%-7.35%2.72%6.37%9.96%11.2%18.45%8.71%5.05%7.33%11.31%-5.13%1.51%10.76%8.2%17.71%15.55%4.38%
Operating Expenses32.48B24.43B19.59B16.25B13.26B13.07B11.85B11.6B10.79B11.28B11.64B11.33B11.35B12.66B12.79B12.9B11.94B11.22B10.47B9.58B8.02B7.52B6.98B6.41B5.57B5.65B5.68B4.98B4.89B4.11B3.63B
OpEx % of Revenue-37.48%43.48%47.63%46.45%46.16%48.27%51.97%50.18%56.46%54.85%56.76%57.88%54.76%56.59%53.12%51.73%51.38%51.38%51.42%51.11%51.36%50.33%50.91%50.31%48.97%52.32%49.79%52.91%51.49%51.8%
Selling, General & Admin12.62B11.09B8.59B6.94B6.07B6.14B5.87B6B5.73B6.18B6.33B6.53B6.62B7.13B7.51B7.88B7.05B6.89B6.63B6.1B4.89B4.5B4.28B4.06B3.42B3.42B3.23B2.76B2.66B2.23B1.89B
SG&A % of Revenue-17.02%19.08%20.34%21.26%21.69%23.92%26.9%26.68%30.94%29.83%32.73%33.75%30.83%33.24%32.45%30.57%31.56%32.53%32.71%31.16%30.71%30.92%32.23%30.91%29.61%29.72%27.57%28.78%27.96%27.04%
Research & Development15.38B13.34B10.99B9.31B7.19B6.93B5.98B5.59B5.05B5.1B5.31B4.8B4.73B5.53B5.28B5.02B4.88B4.33B3.84B3.49B3.13B3.03B2.69B2.35B2.15B2.24B2.02B1.78B1.74B1.37B1.19B
R&D % of Revenue-20.46%24.4%27.29%25.19%24.47%24.35%25.07%23.5%25.51%25.02%24.03%24.13%23.93%23.35%20.67%21.17%19.81%18.85%18.71%19.94%20.66%19.42%18.68%19.4%19.36%18.58%17.83%18.83%17.15%17%
Other Operating Expenses1000K0000000000000000000000000435.8M439.7M490.4M509.8M543.5M
Operating Income39.83B29.7B17.04B10.79B8.65B7.93B7.21B6B6.03B4.25B3.87B3.59B3.33B5.55B5.02B6.32B6.77B6.37B5.53B4.8B4.13B3.65B3.66B3.5B3.33B3.73B3.56B3.36B2.82B2.44B2.04B
Operating Margin %46.07%45.56%37.83%31.61%30.32%28.01%29.38%26.88%28.04%21.28%18.24%18%16.97%24%22.19%26.01%29.35%29.17%27.13%25.78%26.29%24.91%26.4%27.83%30.04%32.31%32.77%33.63%30.58%30.53%29.21%
Operating Income Growth %-74.27%57.96%24.66%9.08%10.02%20.19%-0.44%41.79%9.78%7.77%7.91%-40%10.62%-20.62%-6.71%6.31%15.23%15.1%16.42%13.07%-0.28%4.48%5.23%-10.78%4.78%5.83%19.09%15.83%19.28%3.15%
EBITDA42B31.69B18.81B12.31B10.18B9.48B8.53B7.23B7.63B5.82B5.37B5.02B4.71B6.99B6.48B7.69B8.1B7.67B6.65B5.85B4.93B4.38B4.26B4.05B3.82B4.18B4B3.8B3.31B2.95B2.59B
EBITDA Margin %48.58%48.62%41.75%36.09%35.65%33.48%34.78%32.4%35.52%29.12%25.29%25.15%24%30.26%28.66%31.67%35.1%35.12%32.65%31.4%31.4%29.87%30.71%32.19%34.49%36.25%36.78%38.02%35.89%36.91%36.98%
EBITDA Growth %48.49%68.52%52.72%21.02%7.33%11.08%18.01%-5.28%31.25%8.37%6.93%6.63%-32.69%7.97%-15.78%-5.05%5.64%15.3%13.67%18.74%12.62%2.79%5.08%6.01%-8.7%4.74%5.05%14.74%12.44%13.93%2.06%
D&A (Non-Cash Add-back)2.17B2B1.77B1.53B1.52B1.55B1.32B1.23B1.61B1.57B1.5B1.43B1.38B1.45B1.46B1.37B1.33B1.3B1.12B1.05B801.8M726.4M597.5M548.5M493M454.9M435.8M439.7M490.4M509.8M543.5M
EBIT42.58B29.7B17.04B7.04B7.14B6.5B7.59B5.67B3.92B2.53B3.56B2.95B3.15B6.05B5.59B5.54B6.71B5.62B-1.08B4.8B4.13B3.65B3.66B3.5B3.33B3.73B3.56B3.36B2.82B2.44B2.04B
Net Interest Income-1.18B-642M-605.4M-312.3M-268.8M-314.4M-326.6M-320.2M-83.2M-58.6M-76.5M-74.2M-27.8M-40.4M-72.8M-106.1M-133.6M-186.1M-17.6M000000000000
Interest Income0153.3M175.2M173.6M62.8M25.4M33M80.4M159.3M166.4M108.7M87M121M119.7M105M79.9M51.9M75.2M210.7M000000000000
Interest Expense1.18B795.3M780.6M485.9M331.6M339.8M359.6M400.6M242.5M225M185.2M161.2M148.8M160.1M177.8M186M185.5M261.3M228.3M000000000000
Other Income/Expense-5.06B-3.96B-4.36B-4.23B-1.85B-1.78B19.1M-733.5M-2.35B-1.95B-497.3M-802.1M-328.4M341.2M392.9M-968.4M-247M-1.01B-6.84B-926.1M-707.4M-931.1M-716.8M-240.1M130M-177.7M299M-118.3M-159.5M462.7M87M
Pretax Income34.77B25.73B12.68B6.55B6.81B6.16B7.23B5.27B3.68B2.3B3.37B2.79B3B5.89B5.41B5.35B6.53B5.36B-1.31B3.88B3.42B2.72B2.94B3.26B3.46B3.55B3.86B3.25B2.67B2.9B2.13B
Pretax Margin %40.21%39.48%28.15%19.21%23.85%21.74%29.46%23.59%17.12%11.54%15.9%13.98%15.3%25.48%23.93%22.03%28.28%24.54%-6.42%20.81%21.78%18.56%21.23%25.92%31.21%30.77%35.52%32.44%28.85%36.32%30.45%
Income Tax7.19B5.09B2.09B1.31B561.6M573.8M1.04B628M529.5M2.39B636.4M381.6M609.8M1.2B1.32B1B1.46B1.03B764.3M923.8M755.3M715.9M1.13B700.9M749.8M742.7M800.9M698.7M568.7M885.2M505.6M
Effective Tax Rate %20.68%19.79%16.48%20.05%8.25%9.32%14.33%11.93%14.39%103.75%18.86%13.68%20.32%20.45%24.4%18.73%22.31%19.21%-58.45%23.83%22.1%26.34%38.47%21.49%21.68%20.91%20.76%21.53%21.34%30.51%23.72%
Net Income27.58B20.64B10.59B5.24B6.24B5.58B6.19B8.32B3.23B-204.1M2.74B2.41B2.39B4.68B4.09B4.35B5.07B4.33B-2.07B2.95B2.66B1.98B1.81B2.56B2.71B2.78B3.06B2.72B2.1B-385.1M1.52B
Net Margin %31.9%31.67%23.51%15.36%21.88%19.71%25.24%37.27%15.04%-1.02%12.9%12.07%12.19%20.27%18.09%17.9%21.97%19.82%-10.17%15.85%16.97%13.52%13.06%20.35%24.45%24.08%28.15%27.2%22.71%-4.82%21.77%
Net Income Growth %49.79%94.9%102.08%-16.08%11.88%-9.88%-25.54%157.38%1683.54%-107.46%13.67%0.75%-48.97%14.58%-5.96%-14.24%17.11%308.93%-170.16%10.9%34.51%9.36%-29.32%-5.43%-2.59%-9.09%12.38%29.7%644.77%-125.28%-33.5%
Net Income (Continuing)27.58B20.64B10.59B5.24B6.24B5.58B6.19B4.64B3.15B-86.4M2.74B2.41B2.39B4.68B4.09B4.35B5.07B4.33B-2.07B2.95B2.66B2B1.81B2.56B2.71B2.81B3.06B2.55B2.1B2.02B1.63B
Discontinued Operations00000003.68B81.4M-117.7M00000000000000000174.3M8.8M-2.4B-102.2M
Minority Interest0079.5M91.8M125.6M175.6M183.6M92.2M1.08B75.7M72.8M19M14.9M9.3M8.7M-6.1M-7.5M1.6M00000000000160M0
EPS (Diluted)30.8722.9511.715.806.575.856.478.693.13-0.192.492.182.154.193.573.904.583.94-1.892.712.451.811.662.372.502.552.792.461.87-0.341.36
EPS Growth %50.73%95.99%101.9%-11.72%12.31%-9.58%-25.55%177.64%1747.37%-107.63%14.22%1.4%-48.69%17.37%-8.46%-14.85%16.24%308.47%-169.74%10.61%35.36%9.04%-29.96%-5.2%-1.96%-8.6%13.41%31.55%650%-125%-32.67%
EPS (Basic)-23.0711.765.836.575.856.478.693.14-0.192.492.182.154.193.573.904.583.94-1.892.712.451.821.672.382.512.582.832.501.91-0.351.39
Diluted Shares Outstanding893.4M898M904.06M903.28M950.18M953.65M956.59M957.53M1.03B1.05B1.1B1.11B1.11B1.12B1.15B1.11B1.11B1.1B1.09B1.09B1.09B1.09B1.09B1.08B1.08B1.09B1.1B1.11B1.12B1.13B1.12B
Basic Shares Outstanding891.9M898M900.61M899.38M950.18M953.65M956.59M957.53M1.03B1.05B1.1B1.11B1.11B1.12B1.15B1.11B1.11B1.1B1.09B1.09B1.09B1.09B1.08B1.08B1.08B1.08B1.08B1.09B1.1B1.1B1.09B
Dividend Payout Ratio-26.09%44.2%77.65%56.62%55.3%43.38%28.97%71.53%-78.85%88.33%87.9%45.27%53.5%50.14%42.71%49.72%-62.77%65.21%83.6%85.07%56.35%49.33%43.42%36.82%36.77%41.84%-49.44%

Key Metrics

Growth RegimeDecelerating
ProfitabilityStrong
Balance SheetHealthy
Cash FlowImproving
Top Statement Risk

Incretin franchise concentration risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Top-Line Growth Re-Accelerated Sharply Then Moderated

According to reported quarterly figures, LLY's revenue rose from $11.3B in 2024Q2 to $24.4B in 2026Q3, with year-over-year growth peaking near 55.5% in 2026Q1 before easing to 38.6% in the latest quarter.

The sequence of growth rates suggests the expansion is being driven largely by the metabolic franchise, consistent with tirzepatide adoption, rather than broad-based portfolio strength. The decline from the 2026Q1 peak implies incremental gains are moderating against a substantially larger base. Investors should monitor whether growth holds as supply constraints ease and competitive pressure from Novo Nordisk intensifies.

Gross Margin Anchored Near 84 Percent

As reported in the income statement history, LLY's gross margin has held between 80.8% and 85.8% across the last ten quarters, with the latest quarter at 83.9%, consistent with a high-value, patent-protected product mix.

Stability of gross margin across rapidly rising volumes suggests pricing power and limited unit-cost pressure from manufacturing scale-up. The modest dip in the most recent quarter may reflect higher production or channel costs during capacity build-out rather than a change in pricing. Gross-to-net dynamics are not fully visible in this data, so margin durability should be checked against future rebate disclosures.

Operating Leverage Has Compressed Recently

Based on LLY's reported figures, operating margin expanded from 39.1% in 2024Q2 to a peak of 47.6% in 2025Q3 before easing to 35.3% in 2026Q3, meaning operating income grew more slowly than revenue in the most recent quarters.

The pattern indicates that R&D and SG&A have grown faster than gross profit in the latest periods, with R&D reaching $4.2B and SG&A $3.1B in 2026Q3. This may reflect deliberate reinvestment in pipeline and commercial launches rather than a loss of efficiency. Whether margins recover depends on whether the spending step-up proves temporary or becomes a permanent cost base.

Margin Compression Could Persist Under Pricing Pressure

Based on reported figures, LLY's operating margin has fallen roughly 12 points from its 2025Q3 peak of 47.6% to 35.3% in 2026Q3, a trajectory that could continue if pricing or payer dynamics tighten further.

The bear case centers on whether the recent decline reflects a structural shift in pricing rather than temporary spending timing. Sustained revenue growth paired with shrinking margins would suggest that volume gains are coming at higher rebate or discount cost, which warrants further investigation. If R&D and SG&A keep rising at current rates, the earnings base could become more sensitive to any slowdown in tirzepatide demand.

Net Income Volatility Warrants Scrutiny

Based on reported figures, LLY's net margin ranged from 8.5% in 2024Q3 to 37.4% in 2026Q1, and diluted EPS of $7.22 in 2026Q3 sits below the 2026Q1 level of $8.26, suggesting non-operating items or tax effects are influencing bottom-line results.

Operating margins remained above 35 percent throughout, so the large swings in net margin point to below-the-line items rather than core operating performance. Stock-based compensation of roughly $140M to $200M per quarter does not appear to explain the variance. Earnings quality would be better assessed once the drivers of these non-operating movements, including collaboration milestones, are isolated.

LLY — Frequently Asked Questions

Quick answers to the most common questions about buying LLY stock.

What was Eli Lilly and Company's (LLY) revenue in 2025?

For fiscal year 2025, Eli Lilly and Company (LLY) reported total revenue of $65.18B. This represents a 831.4% increase compared to $7.00B in 1996.

Is Eli Lilly and Company (LLY) profitable?

Eli Lilly and Company (LLY) is profitable, generating $20.64B in net income for the fiscal year ending 2025 with a net profit margin of 31.7%.

What is Eli Lilly and Company's operating profit margin?

Eli Lilly and Company (LLY) reported an operating income of $29.70B, resulting in an operating profit margin of 45.6%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Eli Lilly and Company's gross profit and gross margin?

Eli Lilly and Company (LLY) generated $54.13B in gross profit for the year, representing a gross profit margin of 83.0%. This demonstrates the company's core pricing power and production efficiency.